IQVIA (IQV) Stock Forecast & Price Target

$197.27 +5.75 (+3.00%)

(As of 12/20/2024 05:31 PM ET)

IQVIA - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
0

Hold
3

Buy
18

Based on 21 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 3 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for IQV.

Consensus Price Target

$255.82
29.68% Upside

According to the 21 analysts' twelve-month price targets for IQVIA, the average price target is $255.82. The highest price target for IQV is $300.00, while the lowest price target for IQV is $212.00. The average price target represents a forecasted upside of 29.68% from the current price of $197.27.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

IQV Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	14 Buy rating(s)	12 Buy rating(s)	10 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$255.82	$256.50	$267.00	$235.46
Forecasted Upside	29.68% Upside	27.09% Upside	10.90% Upside	2.65% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

How to piss off your liberal friends… and profit from it (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	29.68% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent IQV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/20/2024	Stephens 4 of 5 stars	J. Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$250.00	+30.53%
12/13/2024	Bank of America 3 of 5 stars		Lower Target	Buy ➝ Buy	$255.00 ➝ $235.00	+17.54%
12/12/2024	Truist Financial 2 of 5 stars		Lower Target	Buy ➝ Buy	$265.00 ➝ $261.00	+30.29%
12/11/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Dodge Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$270.00 ➝ $270.00	+34.11%
12/11/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$213.00 ➝ $212.00	+4.27%
12/11/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
Get the Latest News and Ratings for IQV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.
11/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$260.00 ➝ $248.00	+28.58%
11/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$279.00 ➝ $240.00	+14.35%
11/4/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$280.00 ➝ $265.00	+26.70%
11/1/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$290.00 ➝ $260.00	+24.32%
11/1/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$260.00 ➝ $255.00	+22.30%
11/1/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$270.00 ➝ $265.00	+27.09%
11/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$270.00 ➝ $255.00	+22.30%
11/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$280.00 ➝ $250.00	+20.00%
10/14/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$276.00	+20.32%
10/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$270.00 ➝ $265.00	+17.33%
7/31/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$266.00 ➝ $242.00	+1.34%
7/23/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$295.00 ➝ $300.00	+24.28%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
12/11/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$190.00 ➝ $225.00	+4.52%
10/10/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$250.00 ➝ $229.00	+14.76%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$260.00	+17.71%
8/2/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$255.00 ➝ $281.00	+28.44%
5/1/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$235.00 ➝ $220.00	+16.88%
2/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$265.00	+14.17%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:29 PM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

Recent institutional investment activity indicates strong confidence in IQVIA Holdings Inc., with MML Investors Services LLC increasing its stake by 6.3%, reflecting a positive outlook on the company's future performance.
The stock is currently trading at $206.57, which is significantly below its 12-month high of $261.73, suggesting potential for price appreciation as the market recognizes the company's value.
IQVIA Holdings Inc. has a high percentage of institutional ownership at 89.62%, which often indicates stability and confidence from large investors, potentially leading to less volatility in the stock price.
Analysts have a consensus rating of "Moderate Buy" for IQVIA Holdings Inc., with a price target averaging $256.50, suggesting that there is room for growth in the stock price based on analyst expectations.
The company operates in the growing life sciences sector, providing advanced analytics and technology solutions, which positions it well to benefit from increasing demand for healthcare data and research services.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

The company has a debt-to-equity ratio of 1.76, indicating a higher level of debt compared to equity, which could pose risks if the company faces financial challenges or if interest rates rise.
Recent price target reductions by analysts, such as JPMorgan Chase lowering its target from $279.00 to $240.00, may signal concerns about the company's near-term performance and market conditions.
IQVIA Holdings Inc. has a quick ratio of 0.81, which is below 1, suggesting that the company may not have enough liquid assets to cover its short-term liabilities, raising concerns about its liquidity position.
Despite a strong institutional backing, the stock has experienced fluctuations, with a 12-month low of $187.62, indicating potential volatility that could deter risk-averse investors.
With five analysts rating the stock as a hold, there may be a lack of strong bullish sentiment in the market, which could limit upward momentum in the stock price.

IQV Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $255.82, with a high forecast of $300.00 and a low forecast of $212.00.
: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 3 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IQV shares.
: According to analysts, IQVIA's stock has a predicted upside of 29.68% based on their 12-month stock forecasts.
: IQVIA has been rated by research analysts at Bank of America, Barclays, BTIG Research, Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Redburn Atlantic, Robert W. Baird, Royal Bank of Canada, Stephens, TD Cowen, The Goldman Sachs Group, Truist Financial, and William Blair in the past 90 days.
: Analysts like IQVIA more than other "medical" companies. The consensus rating score for IQVIA is 2.90 while the average consensus rating score for "medical" companies is 2.81. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

How to piss off your liberal friends… and profit from it (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

This page (NYSE:IQV) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Stock Forecast & Price Target